EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bioactive Secondary Metabolites from an Arctic Marine-Derived Strain, Streptomyces sp. MNP-1, Using the OSMAC Strategy

Mengna Wu, Zijun Liu, Jiahui Wang, Wentao Hu, Huawei Zhang iD

Molecules · 2025

DOI: 10.3390/molecules30081657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Mengna Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China. Hauptthemen laut MEDLINE: Streptomyces, Secondary Metabolism, Anti-Infective Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An Arctic marine-derived strain, MNP-1, was characterized by a combined methodological approach, incorporating a variety of analytical techniques including morphological features, biochemical characteristics, and 16S ribosomal RNA (rRNA) sequence analysis. The chemical investigation of Streptomyces sp. MNP-1 using the OSMAC (one strain many compounds) strategy yielded the isolation of twenty known compounds (1–20), which were unambiguously identified by various spectroscopic approaches including 1H and 13C NMR and ESI-MS (previously reported data). Bioassay results indicated that compounds 2, 3, 5, 9, 14, 15, and 20 had antimicrobial activity against human pathogenic strains including Staphylococcus aureus, Escherichia coli, and Candida albicans with MIC values ranging from 4 to 32 μg/mL, and compounds 3 and 14 exhibited moderate inhibitory activity on A549, MCF-7, and HepG2 tumor lines showing IC50 values within the range of 19.88 to 35.82 µM. These findings suggest that Streptomyces sp. MNP-1 is one of the prolific manufacturers of bioactive secondary metabolites with therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StreptomycesSecondary MetabolismAnti-Infective AgentsHumansMicrobial Sensitivity TestsCandida albicansStaphylococcus aureusArctic RegionsRNA, Ribosomal, 16SAntineoplastic AgentsEscherichia coliHep G2 CellsCell Line, TumorAnti-Bacterial Agents

Stichwörter der Autor:innen

OSMAC strategyStreptomycesanticancerantimicrobial activityextremophilesecondary metabolite

Substanzen

Anti-Infective AgentsRNA, Ribosomal, 16SAntineoplastic AgentsAnti-Bacterial Agents

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.
  • College of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.

ORCID-Profile: Huawei Zhang

Förderung

  • the National Key Research and Development Program of China
  • National Key Research and Development Program of China

Zitieren

APA

Wu, M., Liu, Z., Wang, J., Hu, W., & Zhang, H. (2025). Bioactive Secondary Metabolites from an Arctic Marine-Derived Strain, Streptomyces sp. MNP-1, Using the OSMAC Strategy. Molecules. https://doi.org/10.3390/molecules30081657

Vancouver

Wu M, Liu Z, Wang J, Hu W, Zhang H. Bioactive Secondary Metabolites from an Arctic Marine-Derived Strain, Streptomyces sp. MNP-1, Using the OSMAC Strategy. Molecules. 2025. doi:10.3390/molecules30081657

BibTeX
@article{Wu2025,
  author = {Wu, Mengna and Liu, Zijun and Wang, Jiahui and Hu, Wentao and Zhang, Huawei},
  title = {Bioactive Secondary Metabolites from an Arctic Marine-Derived Strain, Streptomyces sp. MNP-1, Using the OSMAC Strategy},
  journal = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30081657}
}
Kostenlos starten →